The FDA warned of newly discovered potential drug interaction that may reduce effectiveness of COVID-19 treatment
On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) warned health care providers about a newly…
-
-
The FDA revoked Emergency Use Authorization for chloroquine and hydroxychloroquine
On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that…
-
NIH launched analytics platform to harness nationwide COVID-19 patient data to speed treatments
On Jun. 15, 2020, the NIH announced it had launched a centralized, secure enclave to store and study…
-
Biotechnology | Diagnostics | Disease | FDA | Medical Device | Neurology | Therapeutics
The FDA permitted marketing of first game-based digital therapeutic to improve attention function in children with ADHD
On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital…
-
Biotechnology | Diagnostics | Infectious Disease | Polio | Vaccine | WHO
Batavia Biosciences and Valneva collaborated to accelerate development of low-cost inactivated polio vaccine
On Jun. 15, 2020, Batavia Biosciences and Valneva announced a collaboration agreement to accelerate market-access of a low-cost…
-
Super-potent human antibodies protect against COVID-19 in animal tests
On Jun. 15, 2020, a team led by Scripps Research discovered antibodies in the blood of recovered COVID-19…
-
Mayo Clinic Study of Humanigen’s lenzilumab showed rapid recovery and discharged in severe and critical COVID-19 patients
On Jun. 15, 2020, Humanigen announced data on the first clinical use of lenzilumab in 12 COVID-19 patients….
-
Lilly begans phase 3 clinical trial with baricitinib for hospitalized COVID-19 patients
On Jun. 15, 2020, Eli Lilly announced that the first patient has been enrolled in a Phase 3…
-
Catalent announced agreement with AstraZeneca to manufacture COVID-19 vaccine candidate
On Jun. 15, 2020, Catalent announced that it will provide vial filling and packaging capacity to AstraZeneca at…
-
SIGA Technologies announced Department of Defense increased funding to develop posteExposure prophylactic indication for TPOXX
On Jun. 15, 2020, SIGA Technologies announced the U.S. Department of Defense (DoD) increased research and development funding…
-
Immunic announced first patients dosed in its phase 2, CALVID-1 clinical trial of IMU-838 in COVID-19
On Jun. 15, 2020, Immunic announced dosing of the first patients in its phase 2, CALVID-1 clinical trial…
-
Cleveland Clinic researchers developed first model to predict likelihood of testing positive for COVID-19 and outcomes from the disease
On Jun. 15, 2020, Cleveland Clinic researchers announced they had developed the worldﾒs first risk prediction model for…
-
McKesson to distribute COVID-19 vaccines in support of Operation Warp Speed
On Jun. 14, 2020, McKesson announced that it had expanded its existing partnership with the Centers for Disease…
-
AstraZeneca to supply Europe with up to 400 million doses of Oxford Universityﾒs vaccine at no profit
On Jun. 13, 2020, AstraZeneca announced an agreement with Europeﾒs Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France,…
-
A cluster of COVID-19 in Beijing, People’s Republic of China was reported
On Jun. 13, 2020, officials from the WHO National Health Commission and Beijing Health Commission announced preliminary investigations…
-
Dr. Reddy’s Laboratories entered into a licensing agreement with Gilead Sciences for Remdesivir
On Jun. 13, 2020, Dr. Reddy’s Laboratories announced that it had entered into a non-exclusive Licensing Agreement with…
-
Sinovac announced positive preliminary results of phase I/II clinical trials for inactivated vaccine candidate against COVID-19
On Jun. 13, 2020, Sinovac Biotech announced positive preliminary results of phase I/II clinical trial for the Companyﾒs…
-
FDA approved HPV vaccine Gardasil as throat cancer prevention
On Jun. 12, 2020, the FDA announced it had approved an expanded indication for Merck’s GARDASIL9 for the…
-
Mutated coronavirus shows significant boost in infectivity
On Jun. 12, 2020, a tiny genetic mutation in the SARS coronavirus 2 variant circulating throughout Europe and…
-
CIRM board approved two additional COVID-19 projects
On Jun. 12, 2020, the California Institute for Regenerative Medicine (CIRM) awarded $349,999 to Dr. Vaithilingaraja Arumugaswami at…
-
Cue Health received FDA EUA for Its rapid, portable, molecular point-of-care COVID-19 test
On Jun. 12, 2020, Cue Health announced that it had received Emergency Use Authorization from the U.S. Food…
-
Biotechnology | CDC | HIV | Therapeutics
The FDA approved drug to treat infants and children with HIV
On Jun. 12, 2020, the U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Tivicay (dolutegravir) tablets and…
-
ViiV Healthcare announced FDA approval of the first-ever dispersible tablet formulation of dolutegravir for children living with HIV
On Jun. 12, 2020, ViiV Healthcare, a GSK company, with Pfizer and Shionogi Limited, announced the FDA had…
-
Oldest relative of ragworms and earthworms discovered
On Jun. 11, 2020, scientists at the Universities of Oxford, Exeter, Yunnan and Bristol announced they had discovered…
-
Moderna advanced late-stage development of vaccine (mRNA-1273) against COVID-19
On Jun. 11, 2020, Moderna announced progress on late-stage development of mRNA-1273, the Company’s mRNA vaccine candidate against…
-
Innovation Pharma collaborated with regional biocontainment lab on grant application to research Brilacidin as pan-Coronavirus therapeutic
On Jun. 11, 2020, Innovation Pharma announced the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL)…
-
CHF Solutions publication highlights use of ultrafiltration for fluid management in COVID-19 patients
On Jun. 11, 2020, CHF Solutions announced that it has sold Aquadex SmartFlowﾙ consoles and disposables to a…
-
BioCryst’s galidesivir stops Zika viral replication in primate model
On Jun. 11, 2020, BioCryst Pharmaceuticals announced new data published in Science Translational Medicine that show, in a…
-
Regeneron began first clinical trials of anti-viral antibody cocktail REGN-COV2 for treatment and prevention of COVID-19
On Jun. 11, 2020, Regeneron announced initiation of the first clinical trial of REGN-COV2, its investigational dual antibody…
-
Two science publications highlight potential of REGN-COV2 anti-viral antibody cocktail to protect against SARS-CoV-2 escape mutants
On Jun. 11, 2020, Regeneron announced that Science had accepted for publication two papers describing the creation of…
